[go: up one dir, main page]

ES2173858T3 - Analogos de huperzina a. - Google Patents

Analogos de huperzina a.

Info

Publication number
ES2173858T3
ES2173858T3 ES90904089T ES90904089T ES2173858T3 ES 2173858 T3 ES2173858 T3 ES 2173858T3 ES 90904089 T ES90904089 T ES 90904089T ES 90904089 T ES90904089 T ES 90904089T ES 2173858 T3 ES2173858 T3 ES 2173858T3
Authority
ES
Spain
Prior art keywords
huperzina
analogs
medicament
huperzine
cholesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90904089T
Other languages
English (en)
Spanish (es)
Inventor
Alain P Kozikowski
Yan Xia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Application granted granted Critical
Publication of ES2173858T3 publication Critical patent/ES2173858T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
ES90904089T 1989-02-21 1990-02-21 Analogos de huperzina a. Expired - Lifetime ES2173858T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/313,118 US4929731A (en) 1989-02-21 1989-02-21 Method for the synthesis of huperzine A and analogs thereof and compounds useful therein

Publications (1)

Publication Number Publication Date
ES2173858T3 true ES2173858T3 (es) 2002-11-01

Family

ID=23214460

Family Applications (2)

Application Number Title Priority Date Filing Date
ES90904089T Expired - Lifetime ES2173858T3 (es) 1989-02-21 1990-02-21 Analogos de huperzina a.
ES01203687T Expired - Lifetime ES2194003T3 (es) 1989-02-21 1990-02-21 Huperzina a racemica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01203687T Expired - Lifetime ES2194003T3 (es) 1989-02-21 1990-02-21 Huperzina a racemica.

Country Status (9)

Country Link
US (1) US4929731A (fr)
EP (3) EP0460062B1 (fr)
JP (1) JP2933386B2 (fr)
AT (3) ATE219061T1 (fr)
CA (2) CA2296915A1 (fr)
DE (3) DE69033970T2 (fr)
DK (2) DK1167354T3 (fr)
ES (2) ES2173858T3 (fr)
WO (1) WO1990009993A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177082A (en) * 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
US5104880A (en) * 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
US5206393A (en) * 1991-09-30 1993-04-27 Union Carbide Chemicals & Plastics Technology Corporation Oxa-bicyclic polyfunctional compounds and preparation thereof
US5145973A (en) * 1991-09-30 1992-09-08 Union Carbide Chemicals & Plastics Technology Corporation Oxa-Bicyclic polyfunctional compounds and preparation thereof
US5547960A (en) * 1994-09-07 1996-08-20 Mayo Foundation For Medical Education And Research C-10 analogs of huperzine a
USRE38460E1 (en) 1994-12-28 2004-03-09 Shanghai Institute Of Materia Medica Chinese Academy Of Sciences Huperzine A derivatives, their preparation and their use
CN1125725A (zh) * 1994-12-28 1996-07-03 中国科学院上海药物研究所 一类海克林碱衍生物及它的用途
US6524616B1 (en) * 1999-06-25 2003-02-25 Wake Forest University Health Services Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions
US6271379B1 (en) * 2000-03-08 2001-08-07 Georgetown University Intermediates useful for the synthesis of huperzine A
US6436972B1 (en) 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
US6369052B1 (en) 2000-08-07 2002-04-09 Georgetown University Combination of huperzine and nicotinic compounds as a neuroprotective agent
KR100390777B1 (ko) * 2000-12-19 2003-07-10 한국화학연구원 피리돈 유도체의 제조방법
US6967206B2 (en) 2002-12-05 2005-11-22 Access Business Group International Llc Compositions and methods for increasing growth hormone levels
CA2609612C (fr) * 2005-05-23 2014-09-23 President & Fellows Of Harvard College Utilisation d'huperzine pour traiter l'epilepsie
US8097726B2 (en) * 2006-05-17 2012-01-17 Industrial Technology Research Institute Huperzine a compound for treatment of alzheimer's disease
WO2009120774A2 (fr) * 2008-03-25 2009-10-01 Debiopharm S.A. Procédé de préparation d'huperzine a et des dérivés de celle-ci
WO2010028134A2 (fr) * 2008-09-04 2010-03-11 President And Fellows Of Harvard College Traitement de troubles neurologiques à l'aide d'huperzine
CN104496900A (zh) * 2014-12-15 2015-04-08 陕西嘉禾植物化工有限责任公司 一种2-甲氧基-6-酮-5,7,8-三氢-喹啉的制备方法
CN104496998B (zh) * 2014-12-15 2017-07-11 陕西嘉禾生物科技股份有限公司 一种1′‑苄基‑2′‑酮‑5′，7′，8′‑三氢‑螺‑[1，3‑二氧五环‑2]‑喹啉的制备方法
CN109705038B (zh) * 2017-10-25 2020-11-03 广州市朗启医药科技有限责任公司 石杉碱甲的合成方法
CN114716449B (zh) * 2022-04-12 2023-09-29 浙江工业大学 一种2-甲氧基-6-乙二醇缩酮-5,7,8-三氢喹啉的制备方法
CN119431243B (zh) * 2025-01-09 2025-06-10 万邦德制药集团有限公司 一种氘代石杉碱甲化合物或其药学上可接受的盐及其制备方法和应用

Also Published As

Publication number Publication date
DK1167354T3 (da) 2003-09-01
DE69033970D1 (de) 2002-07-18
ATE239709T1 (de) 2003-05-15
CA2047744A1 (fr) 1990-08-22
JP2933386B2 (ja) 1999-08-09
EP1167354A2 (fr) 2002-01-02
EP1026157A3 (fr) 2004-08-11
HK1030604A1 (en) 2001-05-11
WO1990009993A3 (fr) 1990-11-01
WO1990009993A2 (fr) 1990-09-07
ATE330943T1 (de) 2006-07-15
DE69034226D1 (de) 2006-08-03
DE69033970T2 (de) 2002-10-02
DE69034226T2 (de) 2007-06-21
ATE219061T1 (de) 2002-06-15
DK0460062T3 (da) 2002-08-26
ES2194003T3 (es) 2003-11-16
DE69034070T2 (de) 2003-12-18
EP0460062A1 (fr) 1991-12-11
EP1026157B1 (fr) 2006-06-21
EP1026157A2 (fr) 2000-08-09
EP1167354B1 (fr) 2003-05-07
DE69034070D1 (de) 2003-06-12
US4929731A (en) 1990-05-29
CA2047744C (fr) 2000-05-02
EP0460062B1 (fr) 2002-06-12
CA2296915A1 (fr) 1990-08-22
EP1167354A3 (fr) 2002-01-09
EP0460062A4 (en) 1992-07-01

Similar Documents

Publication Publication Date Title
ES2173858T3 (es) Analogos de huperzina a.
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
KR880005932A (ko) 신경중독손상을 감소시키기 위한 약제 조성물
UA26303A1 (uk) Фармацевтичhа композиція, яка має імуhосупресорhу та аhтимікробhу активhість
SE9504661D0 (sv) New compounds
MX9100990A (es) Compuesto monohidrato de furoato de mometasona,al procedimiento para su preparacion y a las composiciones farmaceuticas
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
DE3880047D1 (de) Zusammensetzung eines zusatzes.
IL107870A0 (en) Pharmaceutical compositions having antidepressant activity comprising pramipexol
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
MA19882A1 (fr) Derives d'acides w-amines, leur preparation et utilisation ainsi que les compositions contenant ces acides.
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
SE9504662D0 (sv) New compounds
FI922428A0 (fi) Nya 2-amino-5-cyan-1,4- dihydropyridiner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
FI853228A7 (fi) Uudet -butyrolaktaamit, niiden farmaseuttisesti aktiiviset koostumukset, menetelmät niiden valmistamiseksi ja niiden käyttö lääkeaineina.
EA200000531A1 (ru) Применение кетолидов для профилактики тромботических артериальных осложнений, связанных с атеросклерозом
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
LV10917A (lv) Bambuterina pielietojums lipidu saturu pazeminosu farmaceitisku kompoziciju pagatavosanai
IT7822316A0 (it) Composizione farmaceutica per la somministrazione di pancreatina.
DE3650221D1 (de) Penemderivate.
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
YU2394A (sh) Lizin so 6-hloro-5-fluoro-3-(-2-tenoil)-2-oksindol-1-karboksamida
SE9203296D0 (sv) The use of inositoltrisphate for the preparing of medicaments

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 460062

Country of ref document: ES